<DOC>
	<DOCNO>NCT01981525</DOCNO>
	<brief_summary>Background : - Li Fraumeni Syndrome ( LFS ) highly penetrant , autosomal dominant cancer predisposition disorder . Four main cancer type include sarcoma , adrenocortical carcinoma , breast cancer , malignant brain tumor commonly characterize LFS syndrome include cancer . - Metformin oral biguanide drug approve FDA treatment type II diabetes . Metformin associate reduced cancer risk several epidemiologic study reduce cancer mortality patient type 2 diabetes . - Metformin decrease circulate insulin IGF1 , promote glucose uptake skeletal muscle inhibits gluconeogenesis liver . Elevations circulate insulin IGF1 level associate increase cancer risk . - Preclinical research animal model show metformin may toxic cancer cell lose p53 function . - Lifetime risk cancer LFS patient germline TP53 mutation estimate 70 % age 60 , woman excess lifetime cancer risk ( 100 % ) compare men ( 80 % ) . There currently approve chemopreventive agent patient LFS . - Metformin show safe tolerable diabetic non-diabetics , may ideal candidate chemoprevention cancer population . Objectives : - Determine tolerability oral daily metformin patient LFS cause germline TP53 mutation . - Determine 8 week daily metformin administration effect circulate IGF-1 , insulin , IGFBP3 Eligibility : - Must germline TP53 mutation provide documentation test . - Must adequate organ function . - Age great equal 18 year . Design : - This pilot study assess tolerability daily oral metformin administration patient LFS cause germline TP53 mutation study effect metformin biomarker level subject . - In absence intolerable toxicity , minimum 22 patient take metformin mouth total 14 week discontinue metformin 6 week . The total time study 20 week . - Patients assessed biomarker level ( IGF-1 , insulin , IGFBP3 ) blood sample baseline , week 0 8 .</brief_summary>
	<brief_title>A Pilot Study Metformin Patients With Diagnosis Li-Fraumeni Syndrome</brief_title>
	<detailed_description>Background : - Li Fraumeni Syndrome ( LFS ) highly penetrant , autosomal dominant cancer predisposition disorder . Four main cancer type include sarcoma , adrenocortical carcinoma , breast cancer , malignant brain tumor commonly characterize LFS syndrome include cancer . - Metformin oral biguanide drug approve FDA treatment type II diabetes . Metformin associate reduced cancer risk several epidemiologic study reduce cancer mortality patient type 2 diabetes . - Metformin decrease circulate insulin IGF1 , promote glucose uptake skeletal muscle inhibits gluconeogenesis liver . Elevations circulate insulin IGF1 level associate increase cancer risk . - Preclinical research animal model show metformin may toxic cancer cell lose p53 function . - Lifetime risk cancer LFS patient germline TP53 mutation estimate 70 % age 60 , woman excess lifetime cancer risk ( 100 % ) compare men ( 80 % ) . There currently approve chemopreventive agent patient LFS . - Metformin show safe tolerable diabetic non-diabetics , may ideal candidate chemoprevention cancer population . Objectives : - Determine tolerability oral daily metformin patient LFS cause germline TP53 mutation . - Determine 8 week daily metformin administration effect circulate IGF-1 , insulin , IGFBP3 Eligibility : - Must germline TP53 mutation provide documentation test . - Must adequate organ function . - Age great equal 18 year . Design : - This pilot study assess tolerability daily oral metformin administration patient LFS cause germline TP53 mutation study effect metformin biomarker level subject . - In absence intolerable toxicity , minimum 22 patient take metformin mouth total 14 week discontinue metformin 6 week . The total time study 20 week . - Patients assessed biomarker level ( IGF-1 , insulin , IGFBP3 ) blood sample baseline , week 0 , 8 , 14 20 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Li-Fraumeni Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>INCLUSION CRITERIA : All TP53 germline mutation positive adult patient eligible study . All patient must document TP53 germline mutation . Patients history cancer must remission , surgery complete least 6 month prior enrollment chemotherapy complete least 1 year prior enrollment ( except basel cell carcinoma skin ) . Age great equal 18 year . The dos metformin use study exceed maximum recommend daily dose pediatric population . ECOG performance status 0 1 Karnofsky great equal 70 % Patients must normal organ marrow function define : Leukocytes* : great equal 3,000/microL* Absolute neutrophil count : great equal 1,500/ microL Platelets : great equal 100,000/ microL Total bilirubin : Within normal institutional limit AST ( SGOT ) / ALT ( SGPT ) : less equal 2.5 time institutional upper limit normal Creatinine : Within normal institutional limit OR Creatinine clearance : great equal 60 mL/min/1.73m ( 2 ) serum creatinine &gt; institutional normal Note : If leukopenia idiopathic significant comorbidities exist patient exclude basis WBC . Metformin category B drug use treat gestational diabetes . Levels metformin excrete breast milk appear low clinically significant . However , protocol safety reason , enrol pregnant and/or nursing woman study metformin extensively evaluate nondiabetic pregnant nursing woman . For reason , woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Women nurse advise discontinue breastfeed mother treat metformin . Should woman become pregnant suspect pregnant participating study , inform Drs . Annunziata Walcott , protocol physicians/study team NCI primary care provider immediately . Ability subject understand willingness sign write informed consent document . GENERAL EXCLUSION CRITERIA : Patients stemcell transplantation . Current use metformin antidiabetic agent , hypersensitivity allergy metformin . Patients receive investigational agent . Patients history chronic alcohol use History allergic reaction attribute compound similar chemical biologic composition metformin agent use study . Patients congestive heart failure require pharmacological management . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . EXCLUSION CRITERIA 13CMBT STUDIES : Exclusion criterion 13CMBT study addition general exclusion criterion ( pertain effect oral uptake administer substrate mitochondrial function liver ) : Gastric paresis Short gut syndrome Inflammatory bowel disease* Celiac sprue Pancreatic insufficiency disease Any malabsorption disease/syndrome Chronic PPI use H2 blocker use temporarily discontinue ( least 48 hour ) Any acetaminophen , aspirin , NSAID , statin use within 2 day test ( know affect mitochondrial function ) Drugs interfere mitochondrial function unable discontinue 48 hour prior ( 13 ) MBT test excluded test eligible rest protocol . Any oral steroid use within 2 week test Chronic alcohol use** define &gt; 2 standard drink per day ( 2 beer , 2 glass wine , 2 shot liquor per day ) Inflammatory bowel disease exclusion ( 13 ) CMBT , even well control know effect chronic inflammation bowel steroid use may test . The test analyze exhale CO2 breath affect diet ( carbohydrate heavy ) , exercise , certain pathology like liver disease . Also proinflammatory mediator show cause hepatocellular injury may also interfere result test . The test currently study early detection , noninvasive method liver cirrhosis . Therefore , patient chronic alcohol use consistent regular pattern alcohol consumption may underlie liver disease may affect CO2 measurement . Further , alcohol change NADH/NAD ratio intracellularly study show alcohol inhibit methionine oxidation . Previous protocol utilize ( 13 ) CMBT exclude patient consume great 20 g/day alcohol . A standard drink equivalent approximately 14 g/day alcohol ( one 12 oz beer , one 5 oz glass wine , one shot liquor ) . This information obtain National Institute Health/National Institute Alcohol Abuse Alcoholism ( NIAAA ) : http : //pubs.niaaa.nih.gov/publications/Practitioner/pocketguide/pocket_guide2.htm ) . We also evaluate LFTs clinical concern arise , check PT/PTT albumin . Patients normal liver function substantial history alcohol abuse eligible . EXCLUSION CRITERIA FOR 31PMRS STUDIES : Although patient need sign separate inform consent undergo ( 31 ) PMRS study list include general exclusion criterion information care physician . Exclusion criterion ( 31 ) PMRS study addition general exclusion criterion : Inability perform exercise dominant leg Claustrophobia and/or inability lie flat MRI machine Metal medical implantable device MRI incompatible material Body mass index 19 45 Prior stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 18, 2016</verification_date>
	<keyword>TP53 Mutation</keyword>
	<keyword>Autosomal Dominant Hereditary Disorder</keyword>
	<keyword>Chemoprevention</keyword>
</DOC>